References
- Acharya S, Dilnawaz F, Sahoo SK. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials, 2009;30:5737–50
- Chen Devrim B, Bozkir A. Preparation and in vitro evaluation of surface-modified poly(lactide-co-glycolide) microparticles as biodegradable drug carriers for pulmonary peptide and protein delivery. J Microencapsul, 2014;31:355–62
- Couvreur P. Nanoparticles in drug delivery: Past, present and future. Adv Drug Deliv Rev, 2013;65:21–3
- Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: An overview of biomedical applications. J Control Release, 2012;161:505–22
- Danhier F, Vroman B, Lecouturier N, Crokart N, Pourcelle V, Freichels H, Jérôme C, Marchand-Brynaert J, Feron O, Préat V. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. J Control Release, 2009;140:166–73
- Greish K. Enhanced permeability and retention effect for selective targeting of anticancer nanomedicine: Are we there yet? Drug Discov Today Technol, 2012;9:e161–6
- Hu KL, Shi YB, Jiang WM, Han JY, Huang SX, Jiang XG. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: Preparation, characterization and efficacy in Parkinson’s disease. Int J Pharm, 2011;415:273–83
- Kang CM, Koo HJ, Lee KC, Choe YS, Choi JY, Lee KH, Kima BT. A vascular endothelial growth factor 121 (VEGF121)-based dual PET/optical probe for in vivo imaging of VEGF receptor expression. Biomaterials, 2013;34:6839–45
- Ling GX, Zhang P, Zhang WP, Sun J, Meng XX, Qin YM, Deng YH, He ZHG. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. J Control Release, 2010;148:241–8
- Liu D, Liu F, Liu Z, Wang L, Zhang N. Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody. Mol Pharm, 2011;8:2291–301
- Liu XY, Pestka S, Shi YF. 2012. Recent Advances in Cancer Research and Therapy. Beijing, China: Tsinghua University Press Limited and Published by Elsevier Inc
- Nandakumar V, Geetha V, Chittaranjan S, Doble M. High glycolic poly (DL lactic co glycolic acid) nanoparticles for controlled release of meropenem. Biomed Pharmacother, 2013;65:431–6
- Pawar D, Mangal S, Goswami R, Jaganathan K. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: Effect of mucoadhesive coating on antigen uptake and immune adjuvant activity. Eur J Pharm Biopharm, 2013;85:550–9
- Petrak K. Essential properties of drug-targeting delivery systems. Drug Discov Today, 2005;10:1667–73
- Ramanlal CK, Kumar A, Megraj KVK, Ukawala M, Manjappa AS, Mishra AK, Monkkonen J, Ramachandra MRS. Bone metastasis targeting: A novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel. J Control Release, 2012;158:470–8
- Reardon DA, Turner S, Peters KB, Desjardins A, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Jones LW, Kirkpatrick JP. A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. JNCCN, 2011;9:414–27
- Sarbari A, Fahima D, Sanjeeb KS. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials, 2009;30:5737–50
- Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, Mandal M. ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther, 2010;9:592–603
- Sharma PS, Sharma R, Tyagi T. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: Present and future. Curr Cancer Drug Target, 2011;11:624–53
- Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: Reassessing the target. Cancer Res, 2012;72:1909–14
- Yin XB, Wu LQ, Huang MW, Zhou F, Wang K, Yu X, Wang KY, Fu HQ. Humanized anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles, an antibody conjugate with potent and selective anti-hepatocellular carcinoma activity. Biomed Pharmacother, 2014;68:597–602